nodes	percent_of_prediction	percent_of_DWPC	metapath
Daunorubicin—Doxorubicin—muscle cancer	0.216	1	CrCtD
Daunorubicin—hematologic cancer—muscle cancer	0.17	1	CtDrD
Daunorubicin—Anthracyclines—Doxorubicin—muscle cancer	0.124	0.427	CiPCiCtD
Daunorubicin—Topoisomerase Inhibitors—Etoposide—muscle cancer	0.102	0.35	CiPCiCtD
Daunorubicin—Topoisomerase Inhibitors—Doxorubicin—muscle cancer	0.0647	0.223	CiPCiCtD
Daunorubicin—Idarubicin—Doxorubicin—muscle cancer	0.0457	0.333	CrCrCtD
Daunorubicin—Epirubicin—Doxorubicin—muscle cancer	0.0457	0.333	CrCrCtD
Daunorubicin—Valrubicin—Doxorubicin—muscle cancer	0.0457	0.333	CrCrCtD
Daunorubicin—TOP2B—Etoposide—muscle cancer	0.0221	0.144	CbGbCtD
Daunorubicin—YWHAG—Doxorubicin—muscle cancer	0.0151	0.0981	CbGbCtD
Daunorubicin—ABCC6—Dactinomycin—muscle cancer	0.015	0.0973	CbGbCtD
Daunorubicin—ABCC6—Etoposide—muscle cancer	0.00844	0.0549	CbGbCtD
Daunorubicin—ABCC10—Vincristine—muscle cancer	0.00704	0.0458	CbGbCtD
Daunorubicin—ABCC10—Etoposide—muscle cancer	0.00645	0.0419	CbGbCtD
Daunorubicin—POR—Doxorubicin—muscle cancer	0.00627	0.0407	CbGbCtD
Daunorubicin—ABCC6—Doxorubicin—muscle cancer	0.00576	0.0374	CbGbCtD
Daunorubicin—TOP2A—Etoposide—muscle cancer	0.00449	0.0292	CbGbCtD
Daunorubicin—ABCC1—Dactinomycin—muscle cancer	0.00441	0.0287	CbGbCtD
Daunorubicin—ABCC10—Doxorubicin—muscle cancer	0.0044	0.0286	CbGbCtD
Daunorubicin—ABCC10—Methotrexate—muscle cancer	0.00426	0.0277	CbGbCtD
Daunorubicin—ABCB11—Vincristine—muscle cancer	0.00383	0.0249	CbGbCtD
Daunorubicin—XDH—Doxorubicin—muscle cancer	0.0036	0.0234	CbGbCtD
Daunorubicin—CYP1A1—Dacarbazine—muscle cancer	0.00314	0.0204	CbGbCtD
Daunorubicin—TOP2A—Doxorubicin—muscle cancer	0.00307	0.0199	CbGbCtD
Daunorubicin—ABCG2—Dactinomycin—muscle cancer	0.00295	0.0192	CbGbCtD
Daunorubicin—ABCC1—Vincristine—muscle cancer	0.00272	0.0177	CbGbCtD
Daunorubicin—ABCC1—Etoposide—muscle cancer	0.00249	0.0162	CbGbCtD
Daunorubicin—CYP1B1—Doxorubicin—muscle cancer	0.00239	0.0155	CbGbCtD
Daunorubicin—ABCB11—Doxorubicin—muscle cancer	0.00239	0.0155	CbGbCtD
Daunorubicin—ABCC2—Vincristine—muscle cancer	0.00201	0.0131	CbGbCtD
Daunorubicin—ABCC2—Etoposide—muscle cancer	0.00184	0.012	CbGbCtD
Daunorubicin—ABCG2—Vincristine—muscle cancer	0.00182	0.0118	CbGbCtD
Daunorubicin—ABCC1—Doxorubicin—muscle cancer	0.0017	0.011	CbGbCtD
Daunorubicin—ABCG2—Etoposide—muscle cancer	0.00167	0.0108	CbGbCtD
Daunorubicin—ABCC1—Methotrexate—muscle cancer	0.00165	0.0107	CbGbCtD
Daunorubicin—CYP1A2—Dacarbazine—muscle cancer	0.0014	0.00913	CbGbCtD
Daunorubicin—ABCC2—Doxorubicin—muscle cancer	0.00126	0.00817	CbGbCtD
Daunorubicin—ABCC2—Methotrexate—muscle cancer	0.00122	0.00792	CbGbCtD
Daunorubicin—XDH—Effects of Nitric Oxide—MB—muscle cancer	0.00114	0.26	CbGpPWpGaD
Daunorubicin—ABCG2—Doxorubicin—muscle cancer	0.00114	0.00739	CbGbCtD
Daunorubicin—ABCG2—Methotrexate—muscle cancer	0.0011	0.00716	CbGbCtD
Daunorubicin—ABCB1—Dactinomycin—muscle cancer	0.00107	0.00692	CbGbCtD
Daunorubicin—CYP3A5—Vincristine—muscle cancer	0.00101	0.00655	CbGbCtD
Daunorubicin—CYP3A5—Etoposide—muscle cancer	0.000924	0.006	CbGbCtD
Daunorubicin—CYP1A2—Etoposide—muscle cancer	0.000687	0.00447	CbGbCtD
Daunorubicin—ABCB1—Vincristine—muscle cancer	0.000656	0.00426	CbGbCtD
Daunorubicin—ABCB1—Etoposide—muscle cancer	0.000601	0.00391	CbGbCtD
Daunorubicin—ABCB1—Doxorubicin—muscle cancer	0.00041	0.00266	CbGbCtD
Daunorubicin—ABCB1—Methotrexate—muscle cancer	0.000397	0.00258	CbGbCtD
Daunorubicin—CYP3A4—Vincristine—muscle cancer	0.000393	0.00255	CbGbCtD
Daunorubicin—CYP3A4—Etoposide—muscle cancer	0.00036	0.00234	CbGbCtD
Daunorubicin—YWHAG—Translocation of GLUT4 to the plasma membrane—ASPSCR1—muscle cancer	0.00028	0.064	CbGpPWpGaD
Daunorubicin—CYP3A4—Doxorubicin—muscle cancer	0.000246	0.0016	CbGbCtD
Daunorubicin—TOP2B—Teniposide—Etoposide—muscle cancer	0.000237	0.345	CbGdCrCtD
Daunorubicin—TOP2B—embryo—muscle cancer	0.000227	0.0343	CbGeAlD
Daunorubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MYF5—muscle cancer	0.000226	0.0515	CbGpPWpGaD
Daunorubicin—ABCC6—Podofilox—Etoposide—muscle cancer	0.000211	0.307	CbGdCrCtD
Daunorubicin—ABCC6—renal system—muscle cancer	0.00019	0.0287	CbGeAlD
Daunorubicin—YWHAG—smooth muscle tissue—muscle cancer	0.000186	0.028	CbGeAlD
Daunorubicin—NR5A1—head—muscle cancer	0.000181	0.0273	CbGeAlD
Daunorubicin—TOP2B—smooth muscle tissue—muscle cancer	0.000179	0.027	CbGeAlD
Daunorubicin—YWHAG—renal system—muscle cancer	0.000179	0.027	CbGeAlD
Daunorubicin—NR5A1—testis—muscle cancer	0.000175	0.0264	CbGeAlD
Daunorubicin—XDH—renal system—muscle cancer	0.000174	0.0263	CbGeAlD
Daunorubicin—TOP2B—renal system—muscle cancer	0.000172	0.026	CbGeAlD
Daunorubicin—YWHAG—cardiac atrium—muscle cancer	0.00016	0.0242	CbGeAlD
Daunorubicin—TOP2B—cardiac atrium—muscle cancer	0.000154	0.0233	CbGeAlD
Daunorubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MYOG—muscle cancer	0.000145	0.0332	CbGpPWpGaD
Daunorubicin—YWHAG—tendon—muscle cancer	0.000139	0.0211	CbGeAlD
Daunorubicin—SLC22A2—renal system—muscle cancer	0.000137	0.0206	CbGeAlD
Daunorubicin—YWHAG—bone marrow—muscle cancer	0.000135	0.0204	CbGeAlD
Daunorubicin—TOP2B—tendon—muscle cancer	0.000134	0.0203	CbGeAlD
Daunorubicin—TOP2B—bone marrow—muscle cancer	0.00013	0.0197	CbGeAlD
Daunorubicin—YWHAG—vagina—muscle cancer	0.000129	0.0195	CbGeAlD
Daunorubicin—ABCC6—head—muscle cancer	0.000127	0.0192	CbGeAlD
Daunorubicin—XDH—vagina—muscle cancer	0.000126	0.0191	CbGeAlD
Daunorubicin—TOP2B—vagina—muscle cancer	0.000125	0.0188	CbGeAlD
Daunorubicin—POR—cardiac atrium—muscle cancer	0.000122	0.0184	CbGeAlD
Daunorubicin—YWHAG—head—muscle cancer	0.000119	0.018	CbGeAlD
Daunorubicin—YWHAG—Class I PI3K signaling events mediated by Akt—FOXO4—muscle cancer	0.000118	0.027	CbGpPWpGaD
Daunorubicin—YWHAG—testis—muscle cancer	0.000115	0.0174	CbGeAlD
Daunorubicin—TOP2B—head—muscle cancer	0.000115	0.0174	CbGeAlD
Daunorubicin—YWHAG—Membrane Trafficking—ASPSCR1—muscle cancer	0.000113	0.0258	CbGpPWpGaD
Daunorubicin—TOP2B—testis—muscle cancer	0.000111	0.0168	CbGeAlD
Daunorubicin—ABCB11—testis—muscle cancer	0.00011	0.0166	CbGeAlD
Daunorubicin—ABCC10—renal system—muscle cancer	0.000108	0.0163	CbGeAlD
Daunorubicin—POR—tendon—muscle cancer	0.000106	0.016	CbGeAlD
Daunorubicin—POR—bone marrow—muscle cancer	0.000103	0.0155	CbGeAlD
Daunorubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—TP63—muscle cancer	0.000101	0.0232	CbGpPWpGaD
Daunorubicin—TOP2A—tendon—muscle cancer	9.88e-05	0.0149	CbGeAlD
Daunorubicin—POR—vagina—muscle cancer	9.84e-05	0.0149	CbGeAlD
Daunorubicin—ABCC10—cardiac atrium—muscle cancer	9.65e-05	0.0146	CbGeAlD
Daunorubicin—TOP2A—bone marrow—muscle cancer	9.57e-05	0.0145	CbGeAlD
Daunorubicin—NR5A1—Developmental Biology—MYF6—muscle cancer	9.42e-05	0.0215	CbGpPWpGaD
Daunorubicin—NR5A1—Developmental Biology—MYF5—muscle cancer	9.42e-05	0.0215	CbGpPWpGaD
Daunorubicin—TOP2A—vagina—muscle cancer	9.17e-05	0.0138	CbGeAlD
Daunorubicin—YWHAG—FoxO family signaling—FOXO4—muscle cancer	9.04e-05	0.0206	CbGpPWpGaD
Daunorubicin—CYP1B1—smooth muscle tissue—muscle cancer	8.8e-05	0.0133	CbGeAlD
Daunorubicin—POR—testis—muscle cancer	8.78e-05	0.0133	CbGeAlD
Daunorubicin—YWHAG—Class I PI3K signaling events mediated by Akt—FOXO1—muscle cancer	8.74e-05	0.0199	CbGpPWpGaD
Daunorubicin—ABCC2—renal system—muscle cancer	8.65e-05	0.0131	CbGeAlD
Daunorubicin—CYP1B1—renal system—muscle cancer	8.47e-05	0.0128	CbGeAlD
Daunorubicin—ABCC10—tendon—muscle cancer	8.41e-05	0.0127	CbGeAlD
Daunorubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MED12—muscle cancer	8.22e-05	0.0188	CbGpPWpGaD
Daunorubicin—TOP2A—testis—muscle cancer	8.18e-05	0.0124	CbGeAlD
Daunorubicin—ABCC10—bone marrow—muscle cancer	8.15e-05	0.0123	CbGeAlD
Daunorubicin—ABCC10—vagina—muscle cancer	7.8e-05	0.0118	CbGeAlD
Daunorubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—CALD1—muscle cancer	7.29e-05	0.0166	CbGpPWpGaD
Daunorubicin—ABCC10—testis—muscle cancer	6.96e-05	0.0105	CbGeAlD
Daunorubicin—ABCC1—cardiac atrium—muscle cancer	6.82e-05	0.0103	CbGeAlD
Daunorubicin—ABCC2—tendon—muscle cancer	6.75e-05	0.0102	CbGeAlD
Daunorubicin—YWHAG—FoxO family signaling—FOXO1—muscle cancer	6.68e-05	0.0152	CbGpPWpGaD
Daunorubicin—CYP1B1—tendon—muscle cancer	6.61e-05	0.00999	CbGeAlD
Daunorubicin—YWHAG—SIDS Susceptibility Pathways—TP73—muscle cancer	6.46e-05	0.0147	CbGpPWpGaD
Daunorubicin—TOP2A—Vindesine—Vincristine—muscle cancer	6.07e-05	0.0884	CbGdCrCtD
Daunorubicin—CYP1A2—renal system—muscle cancer	6.07e-05	0.00917	CbGeAlD
Daunorubicin—NR5A1—Developmental Biology—MYOG—muscle cancer	6.07e-05	0.0138	CbGpPWpGaD
Daunorubicin—CYP1A1—renal system—muscle cancer	5.99e-05	0.00905	CbGeAlD
Daunorubicin—ABCC1—tendon—muscle cancer	5.95e-05	0.00898	CbGeAlD
Daunorubicin—CYP3A5—renal system—muscle cancer	5.86e-05	0.00885	CbGeAlD
Daunorubicin—CYP1B1—head—muscle cancer	5.67e-05	0.00856	CbGeAlD
Daunorubicin—ABCC2—testis—muscle cancer	5.59e-05	0.00845	CbGeAlD
Daunorubicin—ABCC1—vagina—muscle cancer	5.52e-05	0.00834	CbGeAlD
Daunorubicin—CYP1B1—testis—muscle cancer	5.48e-05	0.00827	CbGeAlD
Daunorubicin—CYP1A1—cardiac atrium—muscle cancer	5.36e-05	0.0081	CbGeAlD
Daunorubicin—YWHAG—Cell Cycle—BUB1B—muscle cancer	5.03e-05	0.0115	CbGpPWpGaD
Daunorubicin—ABCC1—testis—muscle cancer	4.93e-05	0.00744	CbGeAlD
Daunorubicin—ABCG2—bone marrow—muscle cancer	4.77e-05	0.0072	CbGeAlD
Daunorubicin—CYP1B1—Melatonin metabolism and effects—FOXO1—muscle cancer	4.76e-05	0.0109	CbGpPWpGaD
Daunorubicin—ABCC2—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	4.6e-05	0.0105	CbGpPWpGaD
Daunorubicin—ABCG2—vagina—muscle cancer	4.57e-05	0.0069	CbGeAlD
Daunorubicin—CYP3A4—renal system—muscle cancer	4.4e-05	0.00664	CbGeAlD
Daunorubicin—CYP1A1—vagina—muscle cancer	4.34e-05	0.00655	CbGeAlD
Daunorubicin—CYP3A5—vagina—muscle cancer	4.24e-05	0.00641	CbGeAlD
Daunorubicin—ABCB1—embryo—muscle cancer	4.11e-05	0.00621	CbGeAlD
Daunorubicin—ABCG2—testis—muscle cancer	4.08e-05	0.00616	CbGeAlD
Daunorubicin—CYP1A1—head—muscle cancer	4.01e-05	0.00605	CbGeAlD
Daunorubicin—ABCC1—S1P1 pathway—PTGS2—muscle cancer	3.99e-05	0.00911	CbGpPWpGaD
Daunorubicin—YWHAG—Activation of BH3-only proteins—TP53—muscle cancer	3.94e-05	0.00899	CbGpPWpGaD
Daunorubicin—Myalgia—Dactinomycin—muscle cancer	3.92e-05	0.00184	CcSEcCtD
Daunorubicin—Dermatitis contact—Doxorubicin—muscle cancer	3.91e-05	0.00184	CcSEcCtD
Daunorubicin—Lymphadenopathy—Methotrexate—muscle cancer	3.89e-05	0.00183	CcSEcCtD
Daunorubicin—Discomfort—Dactinomycin—muscle cancer	3.87e-05	0.00182	CcSEcCtD
Daunorubicin—Melaena—Doxorubicin—muscle cancer	3.86e-05	0.00182	CcSEcCtD
Daunorubicin—Influenza like illness—Doxorubicin—muscle cancer	3.84e-05	0.00181	CcSEcCtD
Daunorubicin—TOP2A—Vinorelbine—Vincristine—muscle cancer	3.83e-05	0.0558	CbGdCrCtD
Daunorubicin—TOP2A—Podofilox—Etoposide—muscle cancer	3.83e-05	0.0557	CbGdCrCtD
Daunorubicin—TOP2A—Teniposide—Etoposide—muscle cancer	3.83e-05	0.0557	CbGdCrCtD
Daunorubicin—Thrombophlebitis—Methotrexate—muscle cancer	3.83e-05	0.0018	CcSEcCtD
Daunorubicin—Anaemia—Vincristine—muscle cancer	3.8e-05	0.00179	CcSEcCtD
Daunorubicin—Agitation—Vincristine—muscle cancer	3.78e-05	0.00178	CcSEcCtD
Daunorubicin—Polyuria—Methotrexate—muscle cancer	3.78e-05	0.00177	CcSEcCtD
Daunorubicin—Oedema—Dactinomycin—muscle cancer	3.76e-05	0.00177	CcSEcCtD
Daunorubicin—NR5A1—Developmental Biology—MYOD1—muscle cancer	3.75e-05	0.00855	CbGpPWpGaD
Daunorubicin—Infection—Dactinomycin—muscle cancer	3.73e-05	0.00176	CcSEcCtD
Daunorubicin—Neuropathy—Doxorubicin—muscle cancer	3.71e-05	0.00175	CcSEcCtD
Daunorubicin—Leukopenia—Vincristine—muscle cancer	3.68e-05	0.00173	CcSEcCtD
Daunorubicin—Thrombocytopenia—Dactinomycin—muscle cancer	3.68e-05	0.00173	CcSEcCtD
Daunorubicin—NR5A1—Generic Transcription Pathway—MED12—muscle cancer	3.64e-05	0.00831	CbGpPWpGaD
Daunorubicin—Oesophagitis—Doxorubicin—muscle cancer	3.61e-05	0.0017	CcSEcCtD
Daunorubicin—Anorexia—Dactinomycin—muscle cancer	3.58e-05	0.00168	CcSEcCtD
Daunorubicin—Convulsion—Vincristine—muscle cancer	3.56e-05	0.00168	CcSEcCtD
Daunorubicin—Flushing—Etoposide—muscle cancer	3.55e-05	0.00167	CcSEcCtD
Daunorubicin—Cardiac disorder—Etoposide—muscle cancer	3.55e-05	0.00167	CcSEcCtD
Daunorubicin—Hypertension—Vincristine—muscle cancer	3.55e-05	0.00167	CcSEcCtD
Daunorubicin—Myalgia—Vincristine—muscle cancer	3.5e-05	0.00165	CcSEcCtD
Daunorubicin—Hypertonia—Doxorubicin—muscle cancer	3.47e-05	0.00163	CcSEcCtD
Daunorubicin—Abnormal vision—Doxorubicin—muscle cancer	3.45e-05	0.00162	CcSEcCtD
Daunorubicin—Chills—Etoposide—muscle cancer	3.44e-05	0.00161	CcSEcCtD
Daunorubicin—Mental disability—Doxorubicin—muscle cancer	3.43e-05	0.00161	CcSEcCtD
Daunorubicin—NR5A1—Developmental Biology—MED12—muscle cancer	3.43e-05	0.00782	CbGpPWpGaD
Daunorubicin—Anaphylactoid reaction—Methotrexate—muscle cancer	3.42e-05	0.00161	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Dactinomycin—muscle cancer	3.42e-05	0.00161	CcSEcCtD
Daunorubicin—Alopecia—Etoposide—muscle cancer	3.38e-05	0.00159	CcSEcCtD
Daunorubicin—Lymphadenopathy—Doxorubicin—muscle cancer	3.36e-05	0.00158	CcSEcCtD
Daunorubicin—Oedema—Vincristine—muscle cancer	3.36e-05	0.00158	CcSEcCtD
Daunorubicin—Anaphylactic shock—Vincristine—muscle cancer	3.36e-05	0.00158	CcSEcCtD
Daunorubicin—Infection—Vincristine—muscle cancer	3.34e-05	0.00157	CcSEcCtD
Daunorubicin—Thrombophlebitis—Doxorubicin—muscle cancer	3.32e-05	0.00156	CcSEcCtD
Daunorubicin—Thrombocytopenia—Vincristine—muscle cancer	3.29e-05	0.00155	CcSEcCtD
Daunorubicin—Hepatic function abnormal—Doxorubicin—muscle cancer	3.28e-05	0.00154	CcSEcCtD
Daunorubicin—Decreased appetite—Dactinomycin—muscle cancer	3.27e-05	0.00154	CcSEcCtD
Daunorubicin—Dysgeusia—Etoposide—muscle cancer	3.26e-05	0.00153	CcSEcCtD
Daunorubicin—Hyperhidrosis—Vincristine—muscle cancer	3.25e-05	0.00153	CcSEcCtD
Daunorubicin—Fatigue—Dactinomycin—muscle cancer	3.24e-05	0.00152	CcSEcCtD
Daunorubicin—Back pain—Etoposide—muscle cancer	3.22e-05	0.00152	CcSEcCtD
Daunorubicin—Pain—Dactinomycin—muscle cancer	3.21e-05	0.00151	CcSEcCtD
Daunorubicin—Anorexia—Vincristine—muscle cancer	3.2e-05	0.0015	CcSEcCtD
Daunorubicin—Eye pain—Doxorubicin—muscle cancer	3.18e-05	0.00149	CcSEcCtD
Daunorubicin—Cardiac failure congestive—Doxorubicin—muscle cancer	3.17e-05	0.00149	CcSEcCtD
Daunorubicin—ABCC1—S1P1 pathway—VEGFA—muscle cancer	3.14e-05	0.00717	CbGpPWpGaD
Daunorubicin—Mood swings—Methotrexate—muscle cancer	3.14e-05	0.00148	CcSEcCtD
Daunorubicin—Ataxia—Methotrexate—muscle cancer	3.12e-05	0.00147	CcSEcCtD
Daunorubicin—ABCB1—renal system—muscle cancer	3.11e-05	0.0047	CbGeAlD
Daunorubicin—Feeling abnormal—Dactinomycin—muscle cancer	3.1e-05	0.00146	CcSEcCtD
Daunorubicin—Ill-defined disorder—Etoposide—muscle cancer	3.09e-05	0.00145	CcSEcCtD
Daunorubicin—Anaemia—Etoposide—muscle cancer	3.08e-05	0.00145	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Dactinomycin—muscle cancer	3.07e-05	0.00144	CcSEcCtD
Daunorubicin—Hot flush—Doxorubicin—muscle cancer	3.07e-05	0.00144	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Vincristine—muscle cancer	3.06e-05	0.00144	CcSEcCtD
Daunorubicin—Increased appetite—Doxorubicin—muscle cancer	3.06e-05	0.00144	CcSEcCtD
Daunorubicin—Menopausal symptoms—Doxorubicin—muscle cancer	3.04e-05	0.00143	CcSEcCtD
Daunorubicin—Insomnia—Vincristine—muscle cancer	3.04e-05	0.00143	CcSEcCtD
Daunorubicin—Renal impairment—Doxorubicin—muscle cancer	3.02e-05	0.00142	CcSEcCtD
Daunorubicin—Malaise—Etoposide—muscle cancer	3.01e-05	0.00141	CcSEcCtD
Daunorubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—muscle cancer	2.99e-05	0.00682	CbGpPWpGaD
Daunorubicin—Leukopenia—Etoposide—muscle cancer	2.98e-05	0.0014	CcSEcCtD
Daunorubicin—Body temperature increased—Dactinomycin—muscle cancer	2.97e-05	0.0014	CcSEcCtD
Daunorubicin—Abdominal pain—Dactinomycin—muscle cancer	2.97e-05	0.0014	CcSEcCtD
Daunorubicin—Anaphylactoid reaction—Doxorubicin—muscle cancer	2.97e-05	0.00139	CcSEcCtD
Daunorubicin—Cardiac failure—Doxorubicin—muscle cancer	2.94e-05	0.00138	CcSEcCtD
Daunorubicin—CYP1A1—Melatonin metabolism and effects—FOXO1—muscle cancer	2.93e-05	0.00668	CbGpPWpGaD
Daunorubicin—Loss of consciousness—Etoposide—muscle cancer	2.93e-05	0.00138	CcSEcCtD
Daunorubicin—Decreased appetite—Vincristine—muscle cancer	2.92e-05	0.00137	CcSEcCtD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	2.91e-05	0.00665	CbGpPWpGaD
Daunorubicin—Cough—Etoposide—muscle cancer	2.91e-05	0.00137	CcSEcCtD
Daunorubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—muscle cancer	2.9e-05	0.00661	CbGpPWpGaD
Daunorubicin—Fatigue—Vincristine—muscle cancer	2.89e-05	0.00136	CcSEcCtD
Daunorubicin—Convulsion—Etoposide—muscle cancer	2.89e-05	0.00136	CcSEcCtD
Daunorubicin—Hypertension—Etoposide—muscle cancer	2.88e-05	0.00135	CcSEcCtD
Daunorubicin—Pain—Vincristine—muscle cancer	2.87e-05	0.00135	CcSEcCtD
Daunorubicin—Constipation—Vincristine—muscle cancer	2.87e-05	0.00135	CcSEcCtD
Daunorubicin—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	2.87e-05	0.00135	CcSEcCtD
Daunorubicin—CYP3A5—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	2.87e-05	0.00654	CbGpPWpGaD
Daunorubicin—Chest pain—Etoposide—muscle cancer	2.84e-05	0.00133	CcSEcCtD
Daunorubicin—Affect lability—Doxorubicin—muscle cancer	2.83e-05	0.00133	CcSEcCtD
Daunorubicin—YWHAG—Intrinsic Pathway for Apoptosis—TP53—muscle cancer	2.82e-05	0.00643	CbGpPWpGaD
Daunorubicin—Discomfort—Etoposide—muscle cancer	2.8e-05	0.00132	CcSEcCtD
Daunorubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—muscle cancer	2.79e-05	0.00637	CbGpPWpGaD
Daunorubicin—Hypersensitivity—Dactinomycin—muscle cancer	2.77e-05	0.0013	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Vincristine—muscle cancer	2.75e-05	0.00129	CcSEcCtD
Daunorubicin—Confusional state—Etoposide—muscle cancer	2.74e-05	0.00129	CcSEcCtD
Daunorubicin—Cardiac arrest—Doxorubicin—muscle cancer	2.73e-05	0.00128	CcSEcCtD
Daunorubicin—Pancytopenia—Methotrexate—muscle cancer	2.72e-05	0.00128	CcSEcCtD
Daunorubicin—Anaphylactic shock—Etoposide—muscle cancer	2.72e-05	0.00128	CcSEcCtD
Daunorubicin—Mood swings—Doxorubicin—muscle cancer	2.72e-05	0.00128	CcSEcCtD
Daunorubicin—Infection—Etoposide—muscle cancer	2.7e-05	0.00127	CcSEcCtD
Daunorubicin—Ataxia—Doxorubicin—muscle cancer	2.7e-05	0.00127	CcSEcCtD
Daunorubicin—Asthenia—Dactinomycin—muscle cancer	2.7e-05	0.00127	CcSEcCtD
Daunorubicin—Neutropenia—Methotrexate—muscle cancer	2.68e-05	0.00126	CcSEcCtD
Daunorubicin—Dysuria—Methotrexate—muscle cancer	2.68e-05	0.00126	CcSEcCtD
Daunorubicin—Dehydration—Doxorubicin—muscle cancer	2.67e-05	0.00125	CcSEcCtD
Daunorubicin—Thrombocytopenia—Etoposide—muscle cancer	2.66e-05	0.00125	CcSEcCtD
Daunorubicin—Tachycardia—Etoposide—muscle cancer	2.65e-05	0.00125	CcSEcCtD
Daunorubicin—Body temperature increased—Vincristine—muscle cancer	2.65e-05	0.00125	CcSEcCtD
Daunorubicin—Abdominal pain—Vincristine—muscle cancer	2.65e-05	0.00125	CcSEcCtD
Daunorubicin—TOP2A—Vinblastine—Vincristine—muscle cancer	2.64e-05	0.0383	CbGdCrCtD
Daunorubicin—Dry skin—Doxorubicin—muscle cancer	2.63e-05	0.00124	CcSEcCtD
Daunorubicin—Hyperhidrosis—Etoposide—muscle cancer	2.63e-05	0.00124	CcSEcCtD
Daunorubicin—Anorexia—Etoposide—muscle cancer	2.59e-05	0.00122	CcSEcCtD
Daunorubicin—Diarrhoea—Dactinomycin—muscle cancer	2.57e-05	0.00121	CcSEcCtD
Daunorubicin—YWHAG—LKB1 signaling events—TP53—muscle cancer	2.55e-05	0.00582	CbGpPWpGaD
Daunorubicin—Depression—Methotrexate—muscle cancer	2.55e-05	0.0012	CcSEcCtD
Daunorubicin—Gastritis—Doxorubicin—muscle cancer	2.54e-05	0.00119	CcSEcCtD
Daunorubicin—Renal failure—Methotrexate—muscle cancer	2.51e-05	0.00118	CcSEcCtD
Daunorubicin—Stomatitis—Methotrexate—muscle cancer	2.49e-05	0.00117	CcSEcCtD
Daunorubicin—Conjunctivitis—Methotrexate—muscle cancer	2.48e-05	0.00117	CcSEcCtD
Daunorubicin—Dysphagia—Doxorubicin—muscle cancer	2.48e-05	0.00117	CcSEcCtD
Daunorubicin—Hypersensitivity—Vincristine—muscle cancer	2.47e-05	0.00116	CcSEcCtD
Daunorubicin—Dyspnoea—Etoposide—muscle cancer	2.42e-05	0.00114	CcSEcCtD
Daunorubicin—Somnolence—Etoposide—muscle cancer	2.42e-05	0.00114	CcSEcCtD
Daunorubicin—Angina pectoris—Doxorubicin—muscle cancer	2.42e-05	0.00114	CcSEcCtD
Daunorubicin—Asthenia—Vincristine—muscle cancer	2.41e-05	0.00113	CcSEcCtD
Daunorubicin—Vomiting—Dactinomycin—muscle cancer	2.39e-05	0.00112	CcSEcCtD
Daunorubicin—Rash—Dactinomycin—muscle cancer	2.37e-05	0.00111	CcSEcCtD
Daunorubicin—Decreased appetite—Etoposide—muscle cancer	2.36e-05	0.00111	CcSEcCtD
Daunorubicin—Pancytopenia—Doxorubicin—muscle cancer	2.36e-05	0.00111	CcSEcCtD
Daunorubicin—ABCB1—bone marrow—muscle cancer	2.35e-05	0.00355	CbGeAlD
Daunorubicin—Fatigue—Etoposide—muscle cancer	2.35e-05	0.0011	CcSEcCtD
Daunorubicin—Pain—Etoposide—muscle cancer	2.33e-05	0.00109	CcSEcCtD
Daunorubicin—Constipation—Etoposide—muscle cancer	2.33e-05	0.00109	CcSEcCtD
Daunorubicin—Neutropenia—Doxorubicin—muscle cancer	2.32e-05	0.00109	CcSEcCtD
Daunorubicin—Dysuria—Doxorubicin—muscle cancer	2.32e-05	0.00109	CcSEcCtD
Daunorubicin—TOP2A—Gastric Cancer Network 2—TP53—muscle cancer	2.32e-05	0.00529	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle—CDKN2A—muscle cancer	2.3e-05	0.00524	CbGpPWpGaD
Daunorubicin—Diarrhoea—Vincristine—muscle cancer	2.3e-05	0.00108	CcSEcCtD
Daunorubicin—ABCB1—vagina—muscle cancer	2.25e-05	0.0034	CbGeAlD
Daunorubicin—Feeling abnormal—Etoposide—muscle cancer	2.24e-05	0.00105	CcSEcCtD
Daunorubicin—Nausea—Dactinomycin—muscle cancer	2.23e-05	0.00105	CcSEcCtD
Daunorubicin—YWHAG—Cell Cycle—MDM2—muscle cancer	2.23e-05	0.00509	CbGpPWpGaD
Daunorubicin—Gastrointestinal pain—Etoposide—muscle cancer	2.22e-05	0.00105	CcSEcCtD
Daunorubicin—Dizziness—Vincristine—muscle cancer	2.22e-05	0.00104	CcSEcCtD
Daunorubicin—Visual impairment—Methotrexate—muscle cancer	2.21e-05	0.00104	CcSEcCtD
Daunorubicin—Renal failure—Doxorubicin—muscle cancer	2.17e-05	0.00102	CcSEcCtD
Daunorubicin—Neuropathy peripheral—Doxorubicin—muscle cancer	2.17e-05	0.00102	CcSEcCtD
Daunorubicin—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	2.17e-05	0.00495	CbGpPWpGaD
Daunorubicin—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	2.16e-05	0.00493	CbGpPWpGaD
Daunorubicin—Urticaria—Etoposide—muscle cancer	2.16e-05	0.00102	CcSEcCtD
Daunorubicin—Stomatitis—Doxorubicin—muscle cancer	2.16e-05	0.00101	CcSEcCtD
Daunorubicin—Abdominal pain—Etoposide—muscle cancer	2.15e-05	0.00101	CcSEcCtD
Daunorubicin—Body temperature increased—Etoposide—muscle cancer	2.15e-05	0.00101	CcSEcCtD
Daunorubicin—Conjunctivitis—Doxorubicin—muscle cancer	2.15e-05	0.00101	CcSEcCtD
Daunorubicin—Tinnitus—Methotrexate—muscle cancer	2.14e-05	0.00101	CcSEcCtD
Daunorubicin—Vomiting—Vincristine—muscle cancer	2.13e-05	0.001	CcSEcCtD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	2.13e-05	0.00486	CbGpPWpGaD
Daunorubicin—Cardiac disorder—Methotrexate—muscle cancer	2.13e-05	0.001	CcSEcCtD
Daunorubicin—Rash—Vincristine—muscle cancer	2.12e-05	0.000995	CcSEcCtD
Daunorubicin—Dermatitis—Vincristine—muscle cancer	2.12e-05	0.000994	CcSEcCtD
Daunorubicin—XDH—Selenium Micronutrient Network—PTGS2—muscle cancer	2.11e-05	0.00482	CbGpPWpGaD
Daunorubicin—Headache—Vincristine—muscle cancer	2.1e-05	0.000989	CcSEcCtD
Daunorubicin—ABCB1—head—muscle cancer	2.08e-05	0.00314	CbGeAlD
Daunorubicin—Sinusitis—Doxorubicin—muscle cancer	2.08e-05	0.000976	CcSEcCtD
Daunorubicin—Chills—Methotrexate—muscle cancer	2.06e-05	0.000967	CcSEcCtD
Daunorubicin—Alopecia—Methotrexate—muscle cancer	2.03e-05	0.000953	CcSEcCtD
Daunorubicin—ABCB1—testis—muscle cancer	2.01e-05	0.00304	CbGeAlD
Daunorubicin—Hypersensitivity—Etoposide—muscle cancer	2e-05	0.000942	CcSEcCtD
Daunorubicin—Erythema—Methotrexate—muscle cancer	2e-05	0.000938	CcSEcCtD
Daunorubicin—Nausea—Vincristine—muscle cancer	1.99e-05	0.000938	CcSEcCtD
Daunorubicin—Rhinitis—Doxorubicin—muscle cancer	1.99e-05	0.000936	CcSEcCtD
Daunorubicin—CYP1B1—Tryptophan metabolism—MDM2—muscle cancer	1.97e-05	0.0045	CbGpPWpGaD
Daunorubicin—Dysgeusia—Methotrexate—muscle cancer	1.95e-05	0.000919	CcSEcCtD
Daunorubicin—Asthenia—Etoposide—muscle cancer	1.95e-05	0.000917	CcSEcCtD
Daunorubicin—Back pain—Methotrexate—muscle cancer	1.93e-05	0.000908	CcSEcCtD
Daunorubicin—Pruritus—Etoposide—muscle cancer	1.92e-05	0.000905	CcSEcCtD
Daunorubicin—Visual impairment—Doxorubicin—muscle cancer	1.91e-05	0.0009	CcSEcCtD
Daunorubicin—CYP1B1—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	1.9e-05	0.00434	CbGpPWpGaD
Daunorubicin—NR5A1—Developmental Biology—FOXO1—muscle cancer	1.88e-05	0.00429	CbGpPWpGaD
Daunorubicin—CYP1A2—Melatonin metabolism and effects—FOXO1—muscle cancer	1.87e-05	0.00426	CbGpPWpGaD
Daunorubicin—Diarrhoea—Etoposide—muscle cancer	1.86e-05	0.000875	CcSEcCtD
Daunorubicin—Ill-defined disorder—Methotrexate—muscle cancer	1.85e-05	0.000871	CcSEcCtD
Daunorubicin—Tinnitus—Doxorubicin—muscle cancer	1.85e-05	0.00087	CcSEcCtD
Daunorubicin—TOP2A—Idarubicin—Doxorubicin—muscle cancer	1.85e-05	0.0269	CbGdCrCtD
Daunorubicin—TOP2A—Epirubicin—Doxorubicin—muscle cancer	1.85e-05	0.0269	CbGdCrCtD
Daunorubicin—Anaemia—Methotrexate—muscle cancer	1.85e-05	0.000867	CcSEcCtD
Daunorubicin—Flushing—Doxorubicin—muscle cancer	1.84e-05	0.000866	CcSEcCtD
Daunorubicin—Cardiac disorder—Doxorubicin—muscle cancer	1.84e-05	0.000866	CcSEcCtD
Daunorubicin—ABCC1—Arachidonic acid metabolism—PTGS2—muscle cancer	1.84e-05	0.0042	CbGpPWpGaD
Daunorubicin—CYP1A1—PPARA activates gene expression—MED12—muscle cancer	1.84e-05	0.00419	CbGpPWpGaD
Daunorubicin—Malaise—Methotrexate—muscle cancer	1.8e-05	0.000846	CcSEcCtD
Daunorubicin—Dizziness—Etoposide—muscle cancer	1.8e-05	0.000846	CcSEcCtD
Daunorubicin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—MED12—muscle cancer	1.8e-05	0.0041	CbGpPWpGaD
Daunorubicin—Leukopenia—Methotrexate—muscle cancer	1.79e-05	0.00084	CcSEcCtD
Daunorubicin—Chills—Doxorubicin—muscle cancer	1.78e-05	0.000838	CcSEcCtD
Daunorubicin—CYP1B1—Arachidonic acid metabolism—PTGS2—muscle cancer	1.78e-05	0.00406	CbGpPWpGaD
Daunorubicin—Arrhythmia—Doxorubicin—muscle cancer	1.77e-05	0.000834	CcSEcCtD
Daunorubicin—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	1.77e-05	0.00404	CbGpPWpGaD
Daunorubicin—Alopecia—Doxorubicin—muscle cancer	1.75e-05	0.000825	CcSEcCtD
Daunorubicin—NR5A1—Gene Expression—MED12—muscle cancer	1.75e-05	0.004	CbGpPWpGaD
Daunorubicin—Cough—Methotrexate—muscle cancer	1.74e-05	0.000819	CcSEcCtD
Daunorubicin—ABCG2—HIF-2-alpha transcription factor network—VEGFA—muscle cancer	1.74e-05	0.00396	CbGpPWpGaD
Daunorubicin—Convulsion—Methotrexate—muscle cancer	1.73e-05	0.000813	CcSEcCtD
Daunorubicin—Vomiting—Etoposide—muscle cancer	1.73e-05	0.000813	CcSEcCtD
Daunorubicin—Erythema—Doxorubicin—muscle cancer	1.73e-05	0.000813	CcSEcCtD
Daunorubicin—Rash—Etoposide—muscle cancer	1.71e-05	0.000806	CcSEcCtD
Daunorubicin—Dermatitis—Etoposide—muscle cancer	1.71e-05	0.000805	CcSEcCtD
Daunorubicin—Headache—Etoposide—muscle cancer	1.7e-05	0.000801	CcSEcCtD
Daunorubicin—Myalgia—Methotrexate—muscle cancer	1.7e-05	0.000799	CcSEcCtD
Daunorubicin—Arthralgia—Methotrexate—muscle cancer	1.7e-05	0.000799	CcSEcCtD
Daunorubicin—Chest pain—Methotrexate—muscle cancer	1.7e-05	0.000799	CcSEcCtD
Daunorubicin—Dysgeusia—Doxorubicin—muscle cancer	1.69e-05	0.000796	CcSEcCtD
Daunorubicin—Discomfort—Methotrexate—muscle cancer	1.68e-05	0.000789	CcSEcCtD
Daunorubicin—Back pain—Doxorubicin—muscle cancer	1.67e-05	0.000786	CcSEcCtD
Daunorubicin—Confusional state—Methotrexate—muscle cancer	1.64e-05	0.000772	CcSEcCtD
Daunorubicin—Anaphylactic shock—Methotrexate—muscle cancer	1.63e-05	0.000766	CcSEcCtD
Daunorubicin—Infection—Methotrexate—muscle cancer	1.62e-05	0.000761	CcSEcCtD
Daunorubicin—Nausea—Etoposide—muscle cancer	1.62e-05	0.00076	CcSEcCtD
Daunorubicin—Ill-defined disorder—Doxorubicin—muscle cancer	1.6e-05	0.000754	CcSEcCtD
Daunorubicin—Anaemia—Doxorubicin—muscle cancer	1.6e-05	0.000751	CcSEcCtD
Daunorubicin—Thrombocytopenia—Methotrexate—muscle cancer	1.6e-05	0.00075	CcSEcCtD
Daunorubicin—Agitation—Doxorubicin—muscle cancer	1.59e-05	0.000747	CcSEcCtD
Daunorubicin—Hyperhidrosis—Methotrexate—muscle cancer	1.58e-05	0.00074	CcSEcCtD
Daunorubicin—Malaise—Doxorubicin—muscle cancer	1.56e-05	0.000733	CcSEcCtD
Daunorubicin—Anorexia—Methotrexate—muscle cancer	1.55e-05	0.00073	CcSEcCtD
Daunorubicin—Syncope—Doxorubicin—muscle cancer	1.55e-05	0.000729	CcSEcCtD
Daunorubicin—Leukopenia—Doxorubicin—muscle cancer	1.55e-05	0.000727	CcSEcCtD
Daunorubicin—Palpitations—Doxorubicin—muscle cancer	1.53e-05	0.000718	CcSEcCtD
Daunorubicin—Loss of consciousness—Doxorubicin—muscle cancer	1.52e-05	0.000714	CcSEcCtD
Daunorubicin—Cough—Doxorubicin—muscle cancer	1.51e-05	0.000709	CcSEcCtD
Daunorubicin—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	1.5e-05	0.00342	CbGpPWpGaD
Daunorubicin—Convulsion—Doxorubicin—muscle cancer	1.5e-05	0.000704	CcSEcCtD
Daunorubicin—Hypertension—Doxorubicin—muscle cancer	1.49e-05	0.000702	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Methotrexate—muscle cancer	1.48e-05	0.000698	CcSEcCtD
Daunorubicin—YWHAG—Cell Cycle, Mitotic—BUB1B—muscle cancer	1.47e-05	0.00336	CbGpPWpGaD
Daunorubicin—Insomnia—Methotrexate—muscle cancer	1.47e-05	0.000693	CcSEcCtD
Daunorubicin—Arthralgia—Doxorubicin—muscle cancer	1.47e-05	0.000692	CcSEcCtD
Daunorubicin—Myalgia—Doxorubicin—muscle cancer	1.47e-05	0.000692	CcSEcCtD
Daunorubicin—Chest pain—Doxorubicin—muscle cancer	1.47e-05	0.000692	CcSEcCtD
Daunorubicin—Anxiety—Doxorubicin—muscle cancer	1.47e-05	0.000689	CcSEcCtD
Daunorubicin—Discomfort—Doxorubicin—muscle cancer	1.45e-05	0.000684	CcSEcCtD
Daunorubicin—Dyspnoea—Methotrexate—muscle cancer	1.45e-05	0.000683	CcSEcCtD
Daunorubicin—Somnolence—Methotrexate—muscle cancer	1.45e-05	0.000681	CcSEcCtD
Daunorubicin—Dry mouth—Doxorubicin—muscle cancer	1.44e-05	0.000677	CcSEcCtD
Daunorubicin—Confusional state—Doxorubicin—muscle cancer	1.42e-05	0.000669	CcSEcCtD
Daunorubicin—Decreased appetite—Methotrexate—muscle cancer	1.42e-05	0.000666	CcSEcCtD
Daunorubicin—Anaphylactic shock—Doxorubicin—muscle cancer	1.41e-05	0.000663	CcSEcCtD
Daunorubicin—Oedema—Doxorubicin—muscle cancer	1.41e-05	0.000663	CcSEcCtD
Daunorubicin—Fatigue—Methotrexate—muscle cancer	1.4e-05	0.00066	CcSEcCtD
Daunorubicin—Infection—Doxorubicin—muscle cancer	1.4e-05	0.000659	CcSEcCtD
Daunorubicin—Pain—Methotrexate—muscle cancer	1.39e-05	0.000655	CcSEcCtD
Daunorubicin—Shock—Doxorubicin—muscle cancer	1.39e-05	0.000652	CcSEcCtD
Daunorubicin—Thrombocytopenia—Doxorubicin—muscle cancer	1.38e-05	0.000649	CcSEcCtD
Daunorubicin—Tachycardia—Doxorubicin—muscle cancer	1.38e-05	0.000647	CcSEcCtD
Daunorubicin—Hyperhidrosis—Doxorubicin—muscle cancer	1.36e-05	0.000641	CcSEcCtD
Daunorubicin—Anorexia—Doxorubicin—muscle cancer	1.34e-05	0.000632	CcSEcCtD
Daunorubicin—ABCG2—Fluoropyrimidine Activity—TP53—muscle cancer	1.34e-05	0.00307	CbGpPWpGaD
Daunorubicin—Feeling abnormal—Methotrexate—muscle cancer	1.34e-05	0.000631	CcSEcCtD
Daunorubicin—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	1.33e-05	0.00304	CbGpPWpGaD
Daunorubicin—Gastrointestinal pain—Methotrexate—muscle cancer	1.33e-05	0.000626	CcSEcCtD
Daunorubicin—YWHAG—Cell Cycle—BUB1B—muscle cancer	1.32e-05	0.00301	CbGpPWpGaD
Daunorubicin—Urticaria—Methotrexate—muscle cancer	1.29e-05	0.000608	CcSEcCtD
Daunorubicin—Body temperature increased—Methotrexate—muscle cancer	1.29e-05	0.000605	CcSEcCtD
Daunorubicin—Abdominal pain—Methotrexate—muscle cancer	1.29e-05	0.000605	CcSEcCtD
Daunorubicin—Musculoskeletal discomfort—Doxorubicin—muscle cancer	1.29e-05	0.000604	CcSEcCtD
Daunorubicin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—muscle cancer	1.28e-05	0.00293	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle—TP53—muscle cancer	1.28e-05	0.00292	CbGpPWpGaD
Daunorubicin—Insomnia—Doxorubicin—muscle cancer	1.28e-05	0.0006	CcSEcCtD
Daunorubicin—Dyspnoea—Doxorubicin—muscle cancer	1.26e-05	0.000591	CcSEcCtD
Daunorubicin—Somnolence—Doxorubicin—muscle cancer	1.25e-05	0.00059	CcSEcCtD
Daunorubicin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—MED12—muscle cancer	1.24e-05	0.00283	CbGpPWpGaD
Daunorubicin—Decreased appetite—Doxorubicin—muscle cancer	1.23e-05	0.000577	CcSEcCtD
Daunorubicin—Fatigue—Doxorubicin—muscle cancer	1.22e-05	0.000572	CcSEcCtD
Daunorubicin—CYP1A1—Tryptophan metabolism—MDM2—muscle cancer	1.22e-05	0.00277	CbGpPWpGaD
Daunorubicin—Pain—Doxorubicin—muscle cancer	1.21e-05	0.000567	CcSEcCtD
Daunorubicin—Constipation—Doxorubicin—muscle cancer	1.21e-05	0.000567	CcSEcCtD
Daunorubicin—YWHAG—SIDS Susceptibility Pathways—VEGFA—muscle cancer	1.2e-05	0.00275	CbGpPWpGaD
Daunorubicin—Hypersensitivity—Methotrexate—muscle cancer	1.2e-05	0.000564	CcSEcCtD
Daunorubicin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	1.18e-05	0.0027	CbGpPWpGaD
Daunorubicin—XDH—Metabolism—FH—muscle cancer	1.18e-05	0.00269	CbGpPWpGaD
Daunorubicin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	1.17e-05	0.00267	CbGpPWpGaD
Daunorubicin—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	1.17e-05	0.00267	CbGpPWpGaD
Daunorubicin—Asthenia—Methotrexate—muscle cancer	1.17e-05	0.00055	CcSEcCtD
Daunorubicin—Feeling abnormal—Doxorubicin—muscle cancer	1.16e-05	0.000547	CcSEcCtD
Daunorubicin—Gastrointestinal pain—Doxorubicin—muscle cancer	1.15e-05	0.000542	CcSEcCtD
Daunorubicin—Pruritus—Methotrexate—muscle cancer	1.15e-05	0.000542	CcSEcCtD
Daunorubicin—Urticaria—Doxorubicin—muscle cancer	1.12e-05	0.000527	CcSEcCtD
Daunorubicin—Abdominal pain—Doxorubicin—muscle cancer	1.12e-05	0.000524	CcSEcCtD
Daunorubicin—Body temperature increased—Doxorubicin—muscle cancer	1.12e-05	0.000524	CcSEcCtD
Daunorubicin—Diarrhoea—Methotrexate—muscle cancer	1.11e-05	0.000524	CcSEcCtD
Daunorubicin—ABCB11—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.1e-05	0.00252	CbGpPWpGaD
Daunorubicin—CYP1A1—Arachidonic acid metabolism—PTGS2—muscle cancer	1.1e-05	0.0025	CbGpPWpGaD
Daunorubicin—Dizziness—Methotrexate—muscle cancer	1.08e-05	0.000506	CcSEcCtD
Daunorubicin—Hypersensitivity—Doxorubicin—muscle cancer	1.04e-05	0.000489	CcSEcCtD
Daunorubicin—Vomiting—Methotrexate—muscle cancer	1.04e-05	0.000487	CcSEcCtD
Daunorubicin—TOP2A—Cell Cycle, Mitotic—BUB1B—muscle cancer	1.03e-05	0.00235	CbGpPWpGaD
Daunorubicin—Rash—Methotrexate—muscle cancer	1.03e-05	0.000483	CcSEcCtD
Daunorubicin—Dermatitis—Methotrexate—muscle cancer	1.03e-05	0.000482	CcSEcCtD
Daunorubicin—ABCG2—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	1.02e-05	0.00233	CbGpPWpGaD
Daunorubicin—Headache—Methotrexate—muscle cancer	1.02e-05	0.00048	CcSEcCtD
Daunorubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	1.02e-05	0.00232	CbGpPWpGaD
Daunorubicin—Asthenia—Doxorubicin—muscle cancer	1.01e-05	0.000476	CcSEcCtD
Daunorubicin—Pruritus—Doxorubicin—muscle cancer	9.98e-06	0.000469	CcSEcCtD
Daunorubicin—Nausea—Methotrexate—muscle cancer	9.68e-06	0.000455	CcSEcCtD
Daunorubicin—Diarrhoea—Doxorubicin—muscle cancer	9.65e-06	0.000454	CcSEcCtD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	9.59e-06	0.00219	CbGpPWpGaD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	9.44e-06	0.00215	CbGpPWpGaD
Daunorubicin—Dizziness—Doxorubicin—muscle cancer	9.33e-06	0.000439	CcSEcCtD
Daunorubicin—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	9.23e-06	0.00211	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle—BUB1B—muscle cancer	9.22e-06	0.0021	CbGpPWpGaD
Daunorubicin—YWHAG—Apoptosis—TP53—muscle cancer	9.15e-06	0.00209	CbGpPWpGaD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	9.1e-06	0.00208	CbGpPWpGaD
Daunorubicin—Vomiting—Doxorubicin—muscle cancer	8.97e-06	0.000422	CcSEcCtD
Daunorubicin—Rash—Doxorubicin—muscle cancer	8.9e-06	0.000418	CcSEcCtD
Daunorubicin—Dermatitis—Doxorubicin—muscle cancer	8.89e-06	0.000418	CcSEcCtD
Daunorubicin—Headache—Doxorubicin—muscle cancer	8.84e-06	0.000415	CcSEcCtD
Daunorubicin—ABCB11—Metabolism—FH—muscle cancer	8.69e-06	0.00198	CbGpPWpGaD
Daunorubicin—NR5A1—Developmental Biology—VEGFA—muscle cancer	8.58e-06	0.00196	CbGpPWpGaD
Daunorubicin—Nausea—Doxorubicin—muscle cancer	8.38e-06	0.000394	CcSEcCtD
Daunorubicin—ABCC1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	8.28e-06	0.00189	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	8.01e-06	0.00183	CbGpPWpGaD
Daunorubicin—CYP1A2—Tryptophan metabolism—MDM2—muscle cancer	7.75e-06	0.00177	CbGpPWpGaD
Daunorubicin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	7.47e-06	0.0017	CbGpPWpGaD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	7.17e-06	0.00164	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	7.01e-06	0.0016	CbGpPWpGaD
Daunorubicin—CYP1A2—Arachidonic acid metabolism—PTGS2—muscle cancer	6.99e-06	0.00159	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle, Mitotic—CDKN2A—muscle cancer	6.74e-06	0.00154	CbGpPWpGaD
Daunorubicin—XDH—Metabolism—MED12—muscle cancer	6.66e-06	0.00152	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism—FH—muscle cancer	6.53e-06	0.00149	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism—FH—muscle cancer	6.31e-06	0.00144	CbGpPWpGaD
Daunorubicin—XDH—Metabolism—ENO2—muscle cancer	6.07e-06	0.00139	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle—CDKN2A—muscle cancer	6.02e-06	0.00137	CbGpPWpGaD
Daunorubicin—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	5.98e-06	0.00136	CbGpPWpGaD
Daunorubicin—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	5.88e-06	0.00134	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle—MDM2—muscle cancer	5.84e-06	0.00133	CbGpPWpGaD
Daunorubicin—ABCG2—Metabolism—FH—muscle cancer	5.74e-06	0.00131	CbGpPWpGaD
Daunorubicin—SLC22A2—Metabolism—FH—muscle cancer	5.68e-06	0.0013	CbGpPWpGaD
Daunorubicin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	5.52e-06	0.00126	CbGpPWpGaD
Daunorubicin—SLC22A2—Transmission across Chemical Synapses—MDM2—muscle cancer	5.48e-06	0.00125	CbGpPWpGaD
Daunorubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	5.42e-06	0.00124	CbGpPWpGaD
Daunorubicin—TOP2A—Circadian rythm related genes—TP53—muscle cancer	5.2e-06	0.00119	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	4.93e-06	0.00113	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism—MED12—muscle cancer	4.91e-06	0.00112	CbGpPWpGaD
Daunorubicin—ABCB1—Allograft Rejection—VEGFA—muscle cancer	4.78e-06	0.00109	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle, Mitotic—CDKN2A—muscle cancer	4.71e-06	0.00108	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism—ENO2—muscle cancer	4.48e-06	0.00102	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle—CDKN2A—muscle cancer	4.21e-06	0.000961	CbGpPWpGaD
Daunorubicin—SLC22A2—Neuronal System—MDM2—muscle cancer	4.2e-06	0.000959	CbGpPWpGaD
Daunorubicin—CYP3A5—Metabolism—FH—muscle cancer	4.12e-06	0.000939	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle—MDM2—muscle cancer	4.09e-06	0.000932	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—ENO2—muscle cancer	4.02e-06	0.000916	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism—FH—muscle cancer	3.89e-06	0.000887	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism—MED12—muscle cancer	3.69e-06	0.000842	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—HMGA1—muscle cancer	3.65e-06	0.000833	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism—MED12—muscle cancer	3.57e-06	0.000814	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	3.5e-06	0.000799	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism—ENO2—muscle cancer	3.36e-06	0.000767	CbGpPWpGaD
Daunorubicin—YWHAG—Cell Cycle—TP53—muscle cancer	3.35e-06	0.000765	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—FOXO4—muscle cancer	3.27e-06	0.000747	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism—ENO2—muscle cancer	3.25e-06	0.000742	CbGpPWpGaD
Daunorubicin—ABCG2—Metabolism—MED12—muscle cancer	3.25e-06	0.000741	CbGpPWpGaD
Daunorubicin—SLC22A2—Metabolism—MED12—muscle cancer	3.21e-06	0.000733	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	3.15e-06	0.000718	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	3.11e-06	0.000709	CbGpPWpGaD
Daunorubicin—ABCB1—Metabolism—FH—muscle cancer	3.11e-06	0.000709	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	3e-06	0.000684	CbGpPWpGaD
Daunorubicin—ABCG2—Metabolism—ENO2—muscle cancer	2.96e-06	0.000675	CbGpPWpGaD
Daunorubicin—SLC22A2—Metabolism—ENO2—muscle cancer	2.93e-06	0.000668	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.63e-06	0.0006	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.54e-06	0.00058	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism—FH—muscle cancer	2.48e-06	0.000566	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—FOXO1—muscle cancer	2.42e-06	0.000552	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	2.36e-06	0.000539	CbGpPWpGaD
Daunorubicin—TOP2A—Cell Cycle—TP53—muscle cancer	2.34e-06	0.000535	CbGpPWpGaD
Daunorubicin—CYP3A5—Metabolism—MED12—muscle cancer	2.33e-06	0.000531	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism—MED12—muscle cancer	2.2e-06	0.000501	CbGpPWpGaD
Daunorubicin—CYP3A5—Metabolism—ENO2—muscle cancer	2.12e-06	0.000484	CbGpPWpGaD
Daunorubicin—XDH—Metabolism—PTGS2—muscle cancer	2.11e-06	0.000483	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism—ENO2—muscle cancer	2e-06	0.000457	CbGpPWpGaD
Daunorubicin—CYP3A4—Metabolism—FH—muscle cancer	1.91e-06	0.000437	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—KIT—muscle cancer	1.84e-06	0.00042	CbGpPWpGaD
Daunorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.78e-06	0.000407	CbGpPWpGaD
Daunorubicin—ABCB1—Metabolism—MED12—muscle cancer	1.75e-06	0.0004	CbGpPWpGaD
Daunorubicin—ABCB1—Metabolism—ENO2—muscle cancer	1.6e-06	0.000365	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.57e-06	0.000357	CbGpPWpGaD
Daunorubicin—ABCB11—Metabolism—PTGS2—muscle cancer	1.56e-06	0.000356	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—MDM2—muscle cancer	1.45e-06	0.000331	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism—MED12—muscle cancer	1.4e-06	0.00032	CbGpPWpGaD
Daunorubicin—ABCC1—Disease—PTGS2—muscle cancer	1.4e-06	0.000319	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism—ENO2—muscle cancer	1.28e-06	0.000291	CbGpPWpGaD
Daunorubicin—ABCC1—Metabolism—PTGS2—muscle cancer	1.17e-06	0.000267	CbGpPWpGaD
Daunorubicin—CYP1B1—Metabolism—PTGS2—muscle cancer	1.13e-06	0.000259	CbGpPWpGaD
Daunorubicin—CYP3A4—Metabolism—MED12—muscle cancer	1.08e-06	0.000247	CbGpPWpGaD
Daunorubicin—ABCG2—Metabolism—PTGS2—muscle cancer	1.03e-06	0.000235	CbGpPWpGaD
Daunorubicin—SLC22A2—Metabolism—PTGS2—muscle cancer	1.02e-06	0.000233	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	9.99e-07	0.000228	CbGpPWpGaD
Daunorubicin—CYP3A4—Metabolism—ENO2—muscle cancer	9.86e-07	0.000225	CbGpPWpGaD
Daunorubicin—CYP3A5—Metabolism—PTGS2—muscle cancer	7.38e-07	0.000169	CbGpPWpGaD
Daunorubicin—CYP1A1—Metabolism—PTGS2—muscle cancer	6.98e-07	0.000159	CbGpPWpGaD
Daunorubicin—ABCB1—Metabolism—PTGS2—muscle cancer	5.57e-07	0.000127	CbGpPWpGaD
Daunorubicin—CYP1A2—Metabolism—PTGS2—muscle cancer	4.45e-07	0.000102	CbGpPWpGaD
Daunorubicin—CYP3A4—Metabolism—PTGS2—muscle cancer	3.43e-07	7.83e-05	CbGpPWpGaD
